Wall Street brokerages predict that Gemphire Therapeutics Inc (NASDAQ:GEMP) will announce earnings per share of ($0.42) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Gemphire Therapeutics’ earnings. Gemphire Therapeutics reported earnings per share of ($0.58) during the same quarter last year, which suggests a positive year over year growth rate of 27.6%. The firm is scheduled to issue its next earnings report on Tuesday, May 14th.
On average, analysts expect that Gemphire Therapeutics will report full year earnings of ($2.05) per share for the current year, with EPS estimates ranging from ($2.50) to ($1.59). For the next financial year, analysts forecast that the business will report earnings of ($3.55) per share. Zacks Investment Research’s earnings per share calculations are an average based on a survey of research firms that that provide coverage for Gemphire Therapeutics.
Gemphire Therapeutics (NASDAQ:GEMP) last posted its quarterly earnings results on Friday, March 15th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.41) by $0.15.
Several research firms recently issued reports on GEMP. Zacks Investment Research upgraded Gemphire Therapeutics from a “hold” rating to a “buy” rating and set a $1.50 price target on the stock in a research report on Friday, March 22nd. ValuEngine cut Gemphire Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, January 24th. Five analysts have rated the stock with a hold rating and one has issued a buy rating to the company. Gemphire Therapeutics currently has a consensus rating of “Hold” and an average price target of $14.90.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Virtu Financial LLC purchased a new stake in Gemphire Therapeutics in the 4th quarter worth approximately $27,000. Cary Street Partner Investment Advisory LLC purchased a new stake in Gemphire Therapeutics in the 4th quarter worth approximately $212,000. Finally, BlackRock Inc. lifted its holdings in Gemphire Therapeutics by 2,210.5% in the 3rd quarter. BlackRock Inc. now owns 675,038 shares of the company’s stock worth $1,391,000 after buying an additional 645,822 shares during the period. Institutional investors and hedge funds own 27.17% of the company’s stock.
GEMP opened at $1.27 on Wednesday. Gemphire Therapeutics has a 1 year low of $0.57 and a 1 year high of $11.43. The company has a market cap of $18.12 million, a P/E ratio of -0.74 and a beta of 3.04.
Gemphire Therapeutics Company Profile
Gemphire Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia and non-alcoholic steatohepatitis (NASH). It is developing gemcabene, a novel, once-daily, oral therapy, for high risk cardiovascular patients who are unable to achieve normal levels of LDL-C or triglycerides with currently approved therapies, primarily statin therapy, and for those patients who present with NASH.
Recommended Story: How Do Investors Open a Backdoor Roth IRA?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Gemphire Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemphire Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.